

PRESS RELEASE

innate pharma

NUMBER OF SHARES AND VOTING RIGHTS AND CASH SITUATION OF INNATE PHARMA AS AT DECEMBER 31, 2009

Marseilles, France, January 8, 2010


Following the capital increase reserved to categories of investors executed in December 2009 and pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (*Autorité des Marchés Financiers*, or "AMF") charter, Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) updates its total number of shares outstanding as well as its voting rights as at December 31, 2009:

Total number of shares outstanding:	36 636 794
Voting rights:	36 636 794

Following the capital increase, cash, cash equivalents and current financial instruments amounted to 49.2 million euros as at December 31, 2009.

Innate Pharma will announce its turnover for 2009 on February 5, 2010.

Following the recent announcement of its financial calendar for 2010, the Company amends the date of its General Shareholders Meeting which will eventually take place in Marseilles on May 25, 2010.



PRESS RELEASE

innate pharma

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. The Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006. The Company has two drug candidates currently in Phase II clinical trials. Two of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 80 employees as at December 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code FR0010331421

Ticker code IPH

Disclaimer:

This press release contains information on the markets on which the Company operates and forward-looking statements. Although the Company believes this information and these expectations are based on reasonable assumptions, this information and these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (www.amf-france.org) or on Innate Pharma's website (www.innate-pharma.com).

For additional information, please contact:

Innate Pharma

Laure-Hélène Mercier,
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
investors@innate-pharma.fr

Alize Public Relations

Caroline Carmagnol
Phone: +33 (0)1 42 68 86 40
Mobile: +33 (0)6 64 18 99 59
caroline@alizerp.com